ARTICLE | Emerging Company Profile
Newco, led by ex-Seagen CEO Epstein, announces $140M series A
By Danielle Golovin, Senior Biopharma Analyst
December 19, 2024 12:27 PM UTC
With a fresh infusion of $140 million in series A funding, Ottimo will a advance a PD-1 x VEGFR-2 bifunctional antibody it believes will have a wider therapeutic window than PD-1 x VEGF bispecifics for solid tumors.
Growing interest in simultaneously targeting PD-(L)1 and VEGF has swollen the bispecific pipeline against the two targets. The goal of the drug class is to block angiogenesis specifically in the tumor, thereby reducing systemic side effects while also inducing antitumor immunity. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654484/ottimo-differentiating-from-the-vegf-bispecific-pack-via-vegfr-2